There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments.
Ascendis Pharma (ASND)
Wedbush analyst Andreas Argyrides reiterated a Buy rating on Ascendis Pharma today and set a price target of $192.00. The company’s shares closed last Tuesday at $88.68.
According to TipRanks.com, Argyrides has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $142.25, which is a 62.3% upside from current levels. In a report issued on October 17, Bank of America Securities also maintained a Buy rating on the stock with a $113.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOWL:
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
- Werewolf Therapeutics to Participate in Upcoming Investor Conferences
